Thyroid cancer
Revision as of 12:54, 29 August 2022 by Warner-admin (talk | contribs) (Text replacement - "'''contains verified protocol'''" to "'''contains dosing details in manuscript'''")
Note: most thyroid cancer regimens can be found on dedicated pages:
- Histology-specific:
- Biomarker-specific:
3 regimens on this page
3 variants on this page
|
Guidelines
ATA
- 2015: Guidelines on the management of thyroid nodules and differentiated thyroid cancer PubMed
- 2015: Guidelines for the management of medullary thyroid carcinoma PubMed
- 2012: Guidelines for management of patients with anaplastic thyroid cancer PubMed
ESMO
- 2019: Filetti et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Older
- 2012: Pacini et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
Advanced or metastatic disease
Axitinib monotherapy
Regimen
| Study | Evidence |
|---|---|
| Cohen et al. 2008 (A4061014) | Phase 2 |
Targeted therapy
- Axitinib (Inlyta) 5 mg PO twice per day
Continued indefinitely
References
- A4061014: Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00094055
- Update: Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. Epub 2014 Oct 15. link to original article link to PMC article PubMed
Doxorubicin monotherapy
Regimen
| Study | Evidence |
|---|---|
| Gottlieb et al. 1974 | Non-randomized |
Of historic interest.
Chemotherapy
References
- Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin: experience with 30 patients. N Engl J Med. 1974 Jan 24;290(4):193-7. link to original article PubMed
Sorafenib monotherapy
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Gupta-Abramson et al. 2008 | Phase 2 | ORR: 23% (95% CI, 10-42) |
Targeted therapy
- Sorafenib (Nexavar) 400 mg PO twice per day
Continued indefinitely
References
- Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10;26(29):4714-9. Epub 2008 Jun 9. link to original article contains dosing details in manuscript link to PMC article PubMed